Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Timlin

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The British Journal of Radiology|March 1, 2012
Malignant induction probability maps for radiotherapy using X-ray and proton beamsC Timlin, M Houston, B Jones
The British Journal of Radiology|March 1, 2012
Fast neutron relative biological effects and implications for charged particle therapyB Jones, T S A Underwood, A Carabe-Fernandez, et al.
Medical Physics|February 6, 2015
3D calculation of radiation-induced second cancer risk including dose and tissue response heterogeneitiesC Timlin, D R Warren, B Rowland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patientsA R Mato, B T Hill, N Lamanna, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The British Journal of Radiology|March 1, 2012
Malignant induction probability maps for radiotherapy using X-ray and proton beamsC Timlin, M Houston, B Jones
The British Journal of Radiology|March 1, 2012
Fast neutron relative biological effects and implications for charged particle therapyB Jones, T S A Underwood, A Carabe-Fernandez, et al.
Medical Physics|February 6, 2015
3D calculation of radiation-induced second cancer risk including dose and tissue response heterogeneitiesC Timlin, D R Warren, B Rowland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patientsA R Mato, B T Hill, N Lamanna, et al.
Pageof 1